Volume 55, Issue 3, Pages (March 1999)

Slides:



Advertisements
Similar presentations
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure  William C. Wolf, Hideaki.
Advertisements

Volume 63, Issue 1, Pages (January 2003)
Volume 65, Issue 1, Pages (January 2004)
Volume 66, Issue 3, Pages (September 2004)
Volume 61, Issue 4, Pages (April 2002)
Volume 55, Issue 2, Pages (February 1999)
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis  Y. Huang, W.A. Border, D.A. Lawrence, N.A.
Volume 67, Issue 5, Pages (May 2005)
Volume 64, Issue 1, Pages (July 2003)
Volume 61, Issue 2, (February 2002)
Volume 68, Issue 2, Pages (August 2005)
Volume 68, Issue 5, Pages (November 2005)
Volume 58, Issue 6, Pages (December 2000)
Volume 75, Issue 10, Pages (May 2009)
Volume 68, Issue 1, Pages (July 2005)
Volume 59, Issue 5, Pages (May 2001)
Volume 64, Issue 2, Pages (August 2003)
Volume 56, Issue 3, Pages (September 1999)
Volume 55, Issue 2, Pages (February 1999)
Karl A. Nath, Anthony J. Croatt, Jill J. Haggard, Joseph P. Grande 
Volume 57, Issue 5, Pages (May 2000)
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Volume 63, Issue 2, Pages (February 2003)
Gene transfer of truncated IκBα prevents tubulointerstitial injury
Volume 60, Issue 6, Pages (December 2001)
Volume 53, Issue 5, Pages (May 1998)
Volume 58, Issue 1, Pages (July 2000)
Volume 62, Issue 2, Pages (August 2002)
Volume 62, Issue 3, Pages (September 2002)
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure  William C. Wolf, Hideaki.
Volume 57, Issue 5, Pages (May 2000)
Volume 70, Issue 10, Pages (November 2006)
Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis  J. Mahmood, F. Khan, S. Okada,
Volume 53, Issue 5, Pages (May 1998)
Volume 64, Issue 1, Pages (July 2003)
Volume 61, Issue 6, Pages (June 2002)
Volume 62, Issue 3, Pages (September 2002)
Volume 66, Issue 5, Pages (November 2004)
Volume 63, Issue 1, Pages (January 2003)
Volume 67, Issue 2, Pages (February 2005)
C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis  Gopala K. Rangan, Jeffrey W. Pippin, William.
Volume 66, Issue 4, Pages (October 2004)
B. Li, T. Morioka, M. Uchiyama, T. Oite  Kidney International 
Volume 71, Issue 9, Pages (May 2007)
Volume 82, Issue 3, Pages (August 2012)
Volume 73, Issue 7, Pages (April 2008)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 61, Issue 3, Pages (March 2002)
Volume 56, Issue 5, Pages (November 1999)
Volume 78, Issue 1, Pages (July 2010)
Volume 67, Issue 3, Pages (March 2005)
Volume 69, Issue 11, Pages (June 2006)
Volume 54, Issue 1, Pages (July 1998)
Volume 60, Issue 5, Pages (November 2001)
Volume 69, Issue 7, Pages (April 2006)
Interferon-γ inhibits experimental renal fibrosis
Volume 58, Issue 3, Pages (September 2000)
TGF-β type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis  C.Y. Song, B.C. Kim, H.K. Hong,
Volume 60, Issue 5, Pages (November 2001)
The course of the remnant kidney model in mice
Volume 58, Issue 5, Pages (November 2000)
Volume 58, Issue 4, Pages (October 2000)
Volume 59, Issue 2, Pages (February 2001)
Volume 70, Issue 11, Pages (December 2006)
Volume 58, Issue 3, Pages (September 2000)
Volume 62, Issue 5, (November 2002)
Volume 61, Issue 1, Pages (January 2002)
T-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis  Masashi Haraguchi, Wayne A. Border, Yufeng Huang,
Volume 65, Issue 1, Pages (January 2004)
Volume 75, Issue 2, Pages (January 2009)
Presentation transcript:

Volume 55, Issue 3, Pages 877-889 (March 1999) Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis  Takamichi Nakamura, Jun-Ei Obata, Hideaki Kimura, Shinichi Ohno, Yoji Yoshida, Hiroshi Kawachi, Fujio Shimizu  Kidney International  Volume 55, Issue 3, Pages 877-889 (March 1999) DOI: 10.1046/j.1523-1755.1999.055003877.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Time course of systolic blood pressure. Symbols are: (▪) untreated glomerulonephritis (GN) rats; (⧫) hydralazine-treated GN rats; (▴) cilazapril-treated GN rats; (•) cilazapril plus Hoe 140-treated GN rats; (□) candesartan-treated GN rats; (○) nephrectomized control rats. *P < 0.05 vs. untreated GN rats. Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Time course of urinary protein excretion. Symbols are: (▪) untreated glomerulonephritis (GN) rats; (⧫) hydralazine-treated GN rats; (▴) cilazapril-treated GN rats; (•) cilazapril plus Hoe 140-treated GN rats; (□) candesartan-treated GN rats; (○) nephrectomized control rats. *P < 0.05 vs. untreated GN rats; □○P < 0.05 vs. hydralazine-treated GN rats. Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Time course of body weight. Symbols are: (▪) untreated glomerulonephritis (GN) rats; (⧫) hydralazine-treated GN rats; (▴) cilazapril-treated GN rats; (•) cilazapril plus Hoe 140-treated GN rats; (□) candesartan-treated GN rats; (○) nephrectomized control rats. *P < 0.05 vs. nephrectomized control rats. Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Light micrographs of a glomerulus from untreated glomerulonephritis (GN) rats (A), hydralazine-treated GN rats (B), cilazapril-treated GN rats (C), cilazapril plus Hoe 140-treated GN rats (D), candesartan-treated GN rats (E), and nephrectomized control rats (F) (PAS stain final magnification ×560). Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 Glomerulosclerosis index (GSI) and tubulointerstitial lesion index (TILI) in experimental nephritis. Symbols are: (□) untreated glomerulonephritis (GN) rats; (▨) hydralazine-treated GN rats; () cilazapril-treated GN rats; (▤) cilazapril plus Hoe 140-treated GN rats; (▦) candesartan-treated GN rats; (▪) nephrectomized control rats. *P < 0.001 vs. untreated GN rats; □○P < 0.05 vs. hydralazine-treated GN rats; †P < 0.005; #P < 0.05 vs. uninephrectomized control. Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 6 Light micrographs of a glomerulus from untreated (A), daily intraperitoneally phosphate-buffered saline injected (B), subcutaneously minipump implanted (C) glomerulonephritis (GN) rats, and non-GN control rats (D) (PAS stain; final magnification, ×560). Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 7 Immunofluorescence micrographs of a glomerulus stained with anti-TGF-βbgr; antibody. (A) indicates untreated glomerulonephritis (GN) rats, (B) hydralazine-treated GN rats, (C) cilazapril-treated GN rats, (D) cilazapril plus Hoe 140-treated GN rats, (E) candesartan-treated GN rats, (F) nephrectomized control rats (final magnification ×350). Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 8 Immunofluorescence micrographs of a glomerulus stained with antitype I collagen antibody. (A) indicates untreated glomerulonephritis (GN) rats, (B) hydralazine-treated GN rats, (C) cilazapril-treated GN rats, (D) cilazapril plus Hoe 140-treated GN rats, (E) candesartan-treated GN rats, (F) nephrectomized control rats (final magnification ×350). Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 9 Immunofluorescence micrographs of a glomerulus stained with antitype III collagen antibody. (A) indicates untreated glomerulonephritis (GN) rats, (B) hydralazine-treated GN rats, (C) cilazapril-treated GN rats, (D) cilazapril plus Hoe 140-treated GN rats, (E) candesartan-treated GN rats, (F) nephrectomized control rats (final magnification ×350). Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 10 Semiquantatative evaluation of immunohistochemistry in experimental glomerulonephritis. Symbols are: (□) untreated glomerulonephritis (GN) rats; (▨) hydralazine-treated GN rats; () cilazapril-treated GN rats; (▤) cilazapril plus Hoe 140-treated GN rats; (▦) candesartan-treated GN rats; (▪) nephrectomized control rats. *P < 0.01 vs. untreated GN rats; □○P < 0.01 vs. hydralazine-treated GN rats; #P < 0.01 vs. uninephrectomized control. Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 11 (A) Northern blot analysis. Typical autoradiograms of mRNA for TGF-βbgr; (2.5 kb), collagen I (4.7 and 5.7 kb), collagen III (5.3 kb) from the renal cortex of experimental glomerulonephritis (GN) rats. (B) Renal cortical mRNA levels for TGF-βbgr;, collagen I (col. I), and collagen III (col. III). Symbols are: (□) untreated GN rats; (▨) hydralazine-treated GN rats; () cilazapril-treated GN rats; (▤) cilazapril plus Hoe 140-treated GN rats; (▦) candesartan-treated GN rats; (▪) nephrectomized control rats. *P < 0.01 vs. untreated GN rats; □○P < 0.01 vs. hydralazine-treated GN rats; #P < 0.01 vs. uninephrectomized control. Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Kidney International 1999 55, 877-889DOI: (10. 1046/j. 1523-1755. 1999 Kidney International 1999 55, 877-889DOI: (10.1046/j.1523-1755.1999.055003877.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.